权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

IFlowPlate - A universal platform for vascularizing organoids

IFlowPlate - 血管化类器官的通用平台

基本信息

批准号：
556938-2020
负责人：
Zhang, Boyang
金额：
$ 1.09万
依托单位：
McMaster University
依托单位国家：
加拿大
项目类别：
Idea to Innovation
财政年份：
2020
资助国家：
加拿大
起止时间：
2020-01-01 至 2021-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=706054
关键词：
IFlowPlate universal platform vascularizing organoids

项目摘要

Biological research, which encompasses fundamental research in academic labs, drug discovery in pharmaceutical companies, and clinical research in hospitals requires predictable biological models. In recent years, organoids has emerged and attracted significant attention in academic research as well as in the commercial sectors. Organoids are mini organs that are grown in a dish over time from a single or a small cluster of human stem cells. Though organoids cannot replace humans, they can offer valuable insights into the function of drugs, the mechanism of disease progression, and the process of organ development that cannot be provided by single-cell assay or animal models. However, there is one critical biological component that is missing in all organoids - a perfusable blood vessel network. To solve this problem, we developed a platform (here referred to as IFlowPlate) that can be used to grow an array of perfusable blood vessel network to vascularize organoids on demand Commercialization of our IFlowPlate platform is to provide academic, pharmaceutical and hospital lab with a more physiological model and a way to probe the model with intravascular perfusion by upgrading existing organoid cultures with vasculatures. We propose to commercialize the IFlowPlate by establishing an ecosystem of collaborators and beta testers around IFlowPlate to continuously validate our product and expand its application. The requested funds for a Market Assessment will provide recommendations and data to enable us to created a product development and business for successful technology transfer and positioning in the market.

生物学研究，包括学术实验室的基础研究，制药公司的药物发现和医院的临床研究，需要可预测的生物模型。近年来，类器官已经出现，并在学术研究以及商业部门引起了极大的关注。类器官是在培养皿中随着时间的推移从单个或一小群人类干细胞中生长出来的微型器官。虽然类器官不能取代人类，但它们可以为药物功能、疾病进展机制和器官发育过程提供有价值的见解，而这些都是单细胞分析或动物模型无法提供的。然而，在所有类器官中都缺少一个关键的生物成分-可灌注的血管网络。为了解决这个问题，我们开发了一个平台（这里称为IFlowPlate），可用于生长一系列可灌注的血管网络，以按需血管化类器官我们的IFlowPlate平台的商业化旨在为学术、制药和医院实验室提供一种更具生理学意义的模型，以及通过升级现有的具有血管的类器官培养物来探索具有血管内灌注的模型的方法。我们建议通过围绕IFlowPlate建立合作者和beta测试人员的生态系统来商业化IFlowPlate，以不断验证我们的产品并扩大其应用。市场评估所需的资金将提供建议和数据，使我们能够创建一个产品开发和业务，以实现成功的技术转让和市场定位。